key: cord-0820688-8zkvuzw4
authors: De Giorgi, Ugo; Casadei, Chiara; Bronte, Giuseppe; Altini, Mattia; Martinelli, Giovani
title: High dose chemotherapy in a patient with COVID-19
date: 2020-07-04
journal: Eur J Cancer
DOI: 10.1016/j.ejca.2020.06.026
sha: 2d649f514399dc1ed515fa38f951b8c186f061c2
doc_id: 820688
cord_uid: 8zkvuzw4

nan

The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-25 CoV2) is an unprecedented challenge [1] . High dose chemotherapy (HDCT) with autologous stem 26 cell transplantation (ASCT) represents a potentially curative option for testicular germ cell tumor 27 (TGCT) [2], however, to our knowledge, to date there have been no reports on these regimens in 28 patients with COVID-19.

On March 11 th , 2020 a smoker 33-year-old male, weighting 55 kg, with metastatic TGCT was conditions allowed to discharge patient on April 3 rd with a reduction of alphafetoprotein to 15.6 66 U/mL vs 58 U/mL before the third cycle of HDCT. Discharge weight was stable. On April 11 th the 67 patients was declared cured, due to the negativization of the RT-PCR test for SARS-CoV-2. 68 Liang et al demonstrated that cancer patients are at increased risk of severe COVID-19 [6] .

To the best of our knowledge, we report the first case of a TGCT patient infected by SARS-CoV2 

A novel coronavirus from patients with pneumonia in 102

High-dose 104 chemotherapy and stem-cell rescue for metastatic germ-cell tumors

TI-CE high-dose chemotherapy for patients 107 with previously treated germ cell tumors: results and prognostic factor analysis

International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus 110 Classification: a prognostic factor-based staging system for metastatic germ cell cancers

Food & Drug administration: Emergency use authorizations

Cancer patients in SARS-CoV-2 infection: a nationwide 116 analysis in China

COVID-19 pneumonia: what has CT taught us? Lancet Infect 118

Conflicts of interest: Ugo De Giorgi received advisory board or consultant fees from Merck Sharp & Dohme